Repligen in bid for reagent vendor Maravai, sources say

Maravai Lifesciences Holdings

16/08/2024 16:34

By Anirban Sen
       Aug 16 (Reuters) - Repligen  RGEN.O , a provider of drug
manufacturing equipment, has approached Maravai LifeSciences
Holdings  MRVI.O , a vaccine capping reagent vendor that has a
market value of $2.2 billion, with an acquisition offer, people
familiar with the matter said on Friday. 
    There is no certainty that Maravai will agree to a deal with
Repligen, the sources said. Repligen is also deliberating
whether it should divest some of Maravai's divisions if it
succeeds in acquiring the company, one of the sources added.
    The sources requested anonymity because the matter is
confidential. Spokespeople for Repligen and Maravai did not
immediately respond to requests for comment. 
    Maravai has become a takeover target after it lost nearly
80% of its value from its August 2021 peak, as it struggled to
diversify beyond COVID-19 vaccines after the pandemic subsided. 
    

 (Reporting by Anirban Sen in New York)
 ((Anirban.Sen@thomsonreuters.com; Twitter: @asenjourno; Reuters
Messaging: Signal/Telegram/Whatsapp - +1-646-705-9409))